StartSGEN • BMV
add
Seagen
Seneste lukkekurs
3.711,48 $
Årsinterval
3.711,48 $ - 3.711,48 $
Markedsværdi
43,15 mia. USD
P/E-værdi
-
Udbytteprocent
-
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | sep. 2023info | År til år-ændring |
---|---|---|
Indtægt | 648,65 mio. | 27,11 % |
Driftsudgifter | 262,69 mio. | 24,86 % |
Nettoindtægt | -215,79 mio. | -13,09 % |
Overskudsgrad | -33,27 | 11,02 % |
Earnings per share | -1,15 | -11,65 % |
EBITDA | -209,33 mio. | -19,47 % |
Effektiv afgiftssats | 0,26 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | sep. 2023info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 1,24 mia. | -29,86 % |
Samlede aktiver | 3,63 mia. | 0,42 % |
Samlede passiver | 1,08 mia. | 35,94 % |
Samlet egenkapital | 2,55 mia. | — |
Shares outstanding | 188,66 mio. | — |
Kurs/indre værdi | 274,52 | — |
Afkast af aktiver | -16,01 % | — |
Afkast af kapital | -21,12 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | sep. 2023info | År til år-ændring |
---|---|---|
Nettoindtægt | -215,79 mio. | -13,09 % |
Pengestrøm fra drift | -35,82 mio. | 58,21 % |
Pengestrøm fra investering | 142,49 mio. | 119,31 % |
Pengestrøm fra finansiering | 15,52 mio. | -15,59 % |
Nettoændring i likviditet | 119,90 mio. | 1.958,05 % |
Fri pengestrøm | 71,52 mio. | 1.141,10 % |
Om
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Administrerende direktør
Grundlagt
15. jul. 1997
Hovedkvarter
Website
Ansatte
3.256